Internal Medicine, Endocrinology, Diabetes, & Metabolism · Murfreesboro, TN
NPI
1982692844
Since 2005
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
1272 Garrison Dr
Murfreesboro, TN, 37129
Phone (615) 867-8130
Groups this clinician bills Medicare through
Medicare paid, 2024
$75K
3,595 services
Medicare patients, 2024
276
Average age 74
Drug cost, 2024
$380K
2,612 prescriptions
Company payments, 2025
$826
From 20 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by James K Rone was code J0897 (injection, denosumab, 1 mg), 1,140 times for 13 patients. In total James K Rone billed 3,595 services in 39 codes, and Medicare paid $75K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-06-26.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 1,140 | 13 | $20.51 | $23K |
| 84439 Clinical Chemistry | Office | 451 | 245 | $8.66 | $3,905 |
| 84443 Clinical Chemistry | Office | 446 | 245 | $16.13 | $7,195 |
| 36415 Venipuncture Blood Collection | Office | 444 | 244 | $8.51 | $3,777 |
| 84481 Clinical Chemistry | Office | 414 | 223 | $16.24 | $6,725 |
| 99214 Office E&M - Established | Office | 190 | 142 | $74.98 | $14K |
| 99213 Office E&M - Established | Office | 111 | 106 | $57.51 | $6,384 |
| 80048 Clinical Chemistry | Office | 56 | 42 | $8.03 | $449 |
| 82306 Clinical Chemistry | Office | 49 | 44 | $27.95 | $1,370 |
| 83036 Blood Count | Office | 47 | 34 | $9.52 | $447 |
| 99215 Office E&M - Established | Office | 28 | 27 | $129.13 | $3,616 |
| 84460 Clinical Chemistry | Office | 26 | 22 | $5.19 | $135 |
| 82570 Clinical Chemistry | Office | 26 | 21 | $5.08 | $132 |
| 82043 Clinical Chemistry | Office | 26 | 21 | $5.66 | $147 |
| 83970 Clinical Chemistry | Office | 25 | 21 | $38.98 | $974 |
By year: 2022 $101K for 4,901 services; 2023 $103K for 5,737 services; 2024 $75K for 3,595 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 84439 Clinical Chemistry | 451 | 245 | $8.66 | $3,905 |
| 84443 Clinical Chemistry | 446 | 245 | $16.13 | $7,195 |
| 36415 Venipuncture Blood Collection | 444 | 244 | $8.51 | $3,777 |
| 84481 Clinical Chemistry | 414 | 223 | $16.24 | $6,725 |
| 80048 Clinical Chemistry | 56 | 42 | $8.03 | $449 |
| 82306 Clinical Chemistry | 49 | 44 | $27.95 | $1,370 |
| 83036 Blood Count | 47 | 34 | $9.52 | $447 |
| 82043 Clinical Chemistry | 26 | 21 | $5.66 | $147 |
| 84460 Clinical Chemistry | 26 | 22 | $5.19 | $135 |
| 82570 Clinical Chemistry | 26 | 21 | $5.08 | $132 |
Medicare prescription drug claims, 2024
In 2024, the drug James K Rone prescribed most often to Medicare patients was Synthroid (Levothyroxine Sodium), with 922 prescriptions and refills. In total James K Rone wrote 2,612 Medicare prescriptions that cost $380K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Synthroid Levothyroxine Sodium | 922 | 1,836 | 180 | $81K |
| Levothyroxine Sodium Generic | 607 | 1,442 | 138 | $4,026 |
| Liothyronine Sodium Generic | 333 | 756 | 82 | $9,837 |
| Hydrocortisone Generic | 82 | 162 | 16 | $2,238 |
| Ozempic Semaglutide | 55 | 64 | Under 11 | $56K |
| Metformin Hcl Er Metformin Hcl | 47 | 141 | 13 | $651 |
| Tresiba Flextouch U-100 Insulin Degludec | 42 | 112 | 12 | $34K |
| Vitamin D2 Ergocalciferol (Vitamin D2) | 35 | 91 | 13 | $240 |
| Testosterone Generic | 29 | 30 | Under 11 | $1,989 |
| Farxiga Dapagliflozin Propanediol | 28 | 42 | Under 11 | $24K |
| Cytomel Liothyronine Sodium | 26 | 48 | Under 11 | $970 |
| Tirosint Levothyroxine Sodium | 26 | 32 | Under 11 | $5,380 |
| Novolog Insulin Aspart | 22 | 30 | Under 11 | $5,036 |
| Mounjaro Tirzepatide | 21 | 26 | Under 11 | $28K |
| Novolog Flexpen Insulin Aspart | 20 | 43 | Under 11 | $5,869 |
Brand drugs: 1,711 claims; generic drugs: 830 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid James K Rone $826 ($826 in general payments such as food, travel and fees) from 20 companies. The largest payer was Amgen Inc. with $233.
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. AMGN | 9 | $233 |
| Lilly USA, LLC LLY | 3 | $66.78 |
| Xeris Pharmaceuticals, Inc. | 3 | $62.29 |
| Amneal Pharmaceuticals LLC AMRX | 3 | $54.4 |
| Ascendis Pharma Endocrinology Inc ASND | 3 | $52.24 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $50.52 |
| Radius Health, Inc. | 2 | $42.02 |
| Novo Nordisk Inc NVO | 2 | $39.2 |
| Endo USA, Inc. | 1 | $28.71 |
| ACADIA Pharmaceuticals Inc ACAD | 1 | $25.66 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.